Wordt geladen...
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...
Bewaard in:
| Gepubliceerd in: | J Bone Miner Res |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Inc.
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/ https://ncbi.nlm.nih.gov/pubmed/31411768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|